TY - JOUR T1 - PLacebo response and the company it keeps AU - Arnold L Y1 - 2013/11/01 N1 - 10.1001/jamapediatrics.2013.2704 JO - JAMA Pediatrics SP - 1000 EP - 1001 VL - 167 IS - 11 N2 - In this issue of JAMA Pediatrics, King and colleagues1 treat us to some interesting insights into prognostic indicators, placebo response, and the vagaries of clinical trials. Although the study that provided their data (citalopram hydrobromide vs placebo for stereotyped behavior in autism spectrum disorder2) was a failed trial, they salvage considerable scientific and clinical knowledge from it in the process of investigating the failure to find a difference between the placebo and the active drug. Some of their findings are enlightening, others puzzling or surprising, but all clinically interesting. The interpretation depends partly on the perspective taken: placebo with citalopram as comparator or citalopram with placebo as comparator. The genius of the authors has been to “turn the tables” from the usual approach and focus on the placebo group as the primary group, with the active drug group as the comparator.1 SN - 2168-6203 M3 - doi: 10.1001/jamapediatrics.2013.2704 UR - http://dx.doi.org/10.1001/jamapediatrics.2013.2704 ER -